Clinicopathological and prognostic value of SIRT6 in patients with solid tumors: a meta-analysis and TCGA data review

Xiaojing Wu; Shuyuan Wang; Xuanzhu Zhao; Sizhen Lai; Zhen Yuan; Yixiang Zhan; Kemin Ni; Zhaoce Liu; Lina Liu; Ran Xin; Xingyu Zhou; Xin Yin; Xinyu Liu; Xipeng Zhang; Wei Cui; Chunze Zhang

doi:10.1186/s12935-022-02511-3

Clinicopathological and prognostic value of SIRT6 in patients with solid tumors: a meta-analysis and TCGA data review

Cancer Cell Int. 2022 Feb 16;22(1):84. doi: 10.1186/s12935-022-02511-3.

Authors

Xiaojing Wu^#^{1

2}, Shuyuan Wang^#², Xuanzhu Zhao^#^{1

3}, Sizhen Lai^#^{1

3}, Zhen Yuan², Yixiang Zhan^{1

2}, Kemin Ni^{1

2}, Zhaoce Liu^{1

2}, Lina Liu¹, Ran Xin², Xingyu Zhou², Xin Yin², Xinyu Liu^{1

4}, Xipeng Zhang^{1

5}, Wei Cui⁶, Chunze Zhang^{7

8}

Affiliations

¹ Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, 300121, China.
² School of Medicine, Nankai University, Tianjin, 300071, China.
³ School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
⁴ Tianjin Medical University, Tianjin, 300041, China.
⁵ Tianjin Institute of Coloproctology, Tianjin, 300121, China.
⁶ School of Mathematical Sciences and LPMC, Nankai University, Tianjin, 300071, China. weicui@nankai.edu.cn.
⁷ Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, 300121, China. chunze.zhang@nankai.edu.cn.
⁸ Tianjin Institute of Coloproctology, Tianjin, 300121, China. chunze.zhang@nankai.edu.cn.

^# Contributed equally.

Abstract

Purposes: In addition to its role in cellular progression and cancer, SIRT6, a member of nicotinamide adenine dinucleotide (NAD⁺)-dependent class III deacylase sirtuin family, serves a variety of roles in the body's immune system. In this study, we sought to determine the relationship between the expression of SIRT6 and the clinicopathological outcomes of patients with solid tumours by conducting a meta-analysis of the available data.

Methods: The databases PubMed and ISI Web of Science were searched for relevant literature, and the results were presented here. Using Stata16.0, a meta-analysis was conducted to determine the impact of SIRT6 on clinicopathological characteristics and prognosis in malignancy patients. The results were published in the journal Cancer Research. The dataset from the Cancer Genome Atlas (TCGA) was used to investigate the prognostic significance of SIRT6 in various types of tumors.

Results: The inclusion and exclusion criteria were met by 15 studies. In patients with solid tumours, reduced SIRT6 expression was found to be related with improved overall survival (OS) (HR = 0.66, 95% CI = 0.45-0.97, P < 0.001) as well as improved disease-free survival (DFS) (HR = 0.48, 95% CI = 0.26-0.91, P < 0.001). Low SIRT6 expression was found to be associated with a better OS in breast cancer (HR = 0.49, 95% CI = 0.27-0.89, P = 0.179), but was found to be associated with a worse OS in gastrointestinal cancer (gastric cancer and colon cancer) (HR = 1.83, 95% CI = 1.20-2.79, P = 0.939) after subgroup analysis. In terms of clinicopathological characteristics, SIRT6 expression was found to be linked with distant metastasis (OR = 2.98, 95% CI = 1.59-5.57, P = 0.694). When the data from the TCGA dataset was compared to normal tissue, it was discovered that SIRT6 expression was significantly different in 11 different types of cancers. Meanwhile, reduced SIRT6 expression was shown to be associated with improved OS (P < 0.05), which was consistent with the findings of the meta-analysis. Aside from that, the expression of SIRT6 was found to be associated with both gender and clinical stage.

Conclusion: The overall data of the present meta-analysis indicated that low expression of SIRT6 may predict a favorable survival for patients with solid tumors.

Keywords: Meta-analysis; Prognosis; SIRT6; Solid tumors.

Publication types

Review

Abstract

Publication types

Grants and funding